TABLE 2.
Arginine, nitric oxide, ornithine, citrulline, and phenylalanine kinetics under euglycemic and hyperglycemic conditions prior to intravenous arginine bolus administration in 6 recent-onset KPD patients and 6 age-, gender-, and BMI-matched control participants1
| Euglycemia | Hyperglycemia | |||
|---|---|---|---|---|
| Kinetics, | ||||
| μmol · kg LBM−1 · h−1 | Control (n = 6) | KPD (n = 6) | Control (n = 6) | KPD (n = 6) |
| Arginine flux2 | 55.2 ± 4.23 | 62.8 ± 3.70 | 44.5 ± 2.983 | 49.4 ± 2.203 |
| Arginine synthesis2 (from citrulline) | 7.83 ± 0.57 | 7.48 ± 0.28 | 5.30 ± 0.323 | 5.77 ± 0.673 |
| Arginine flux from synthesis, % | 14.4 ± 1.16 | 12.1 ± 0.78 | 13.1 ± 1.02 | 11.6 ± 1.09 |
| Ornithine flux2 | 24.1 ± 3.46 | 16.3 ± 1.204 | 15.0 ± 1.483 | 13.5 ± 0.81 |
| Nitric oxide synthesis | 0.18 ± 0.05 | 0.19 ± 0.02 | 0.19 ± 0.03 | 0.28 ± 0.07 |
| Citrulline flux2 | 9.17 ± 0.56 | 8.91 ± 0.45 | 7.16 ± 0.633 | 6.96 ± 0.813 |
| Phenylalanine flux5 | 35.7 ± 2.46 | 45.6 ± 2.194 | 36.6 ± 2.61 | 43.9 ± 1.56 |
1All values are means ± SEMs. Cell means were compared by repeated-measures 2-factor ANOVA. KPD, ketosis-prone diabetes; LBM, lean body mass.
2Main effect of glycemic state (euglycemic compared with hyperglycemic), P < 0.05.
3Significantly different from corresponding group in euglycemic condition, P < 0.05 (post hoc Sidak multiple comparison test).
4Significantly different from control group in corresponding clinical condition, P < 0.05 (post hoc Sidak multiple comparison test).
5Main effect of group (control compared with KPD), P < 0.05.